Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study

Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study

Summary: Background: Several COVID-19 vaccines have been licensed. To support the assessment of safety signals, we developed a toolkit to support COVID-19 vaccine monitoring and benefit–risk assessment. We aim to show the application of our toolkit in the EU using thrombosis with thrombocytopenia s...

Full description

Saved in:
Bibliographic Details
Main Authors: Hector Gonzalez Dorta, MSc, Johan Verbeeck, PhD, Jonas Crevecoeur, PhD, Daniel R Morales, PhD, Neilshan Loedy, MSc, Catherine Cohet, PhD, Lander Willem, PhD, Geert Molenberghs, ProfPhD, Niel Hens, ProfPhD, Xavier Kurz, PhD, Chantal Quinten, PhD, Steven Abrams, PhD
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:The Lancet: Digital Health
Online Access:http://www.sciencedirect.com/science/article/pii/S2589750025000251
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2589750025000251

Similar Items